Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Fig. 5

Intraventricular infusion with gene-edited CAR T cells is efficacious against GBM. a U87vIII cells (5 × 103) were implanted orthotopically into NSG mice and treated post-implantation with intraventricular (IVT) effector cells. b Antitumor responses produced by CART-EGFRvIIIΔPD-1 in vivo. Survival curves were estimated for each group using Kaplan–Meier product-limit estimation. Primary comparative analyses of the curves for each group were performed using the log-rank test (*** = p < 0.001). c Bioluminescence imaging of U87vIII tumor growth over time, n = 5 mice

Back to article page